0 9 Synergism Synergism NNP 10 17 between between IN 18 21 the the DT 22 25 CD3 cd3 NN 26 34 antigen- antigen- NN 35 38 and and CC 39 42 CD2 cd2 NN 43 58 antigen-derived antigen-derived JJ 59 66 signals signal NNS 66 67 . . . 68 79 Exploration Exploration NNP 80 82 at at IN 83 86 the the DT 87 92 level level NN 93 95 of of IN 96 105 induction induction NN 106 108 of of IN 109 120 DNA-binding dna-binding JJ 121 129 proteins protein NNS 130 133 and and CC 134 150 characterization characterization NN 151 153 of of IN 154 157 the the DT 158 168 inhibitory inhibitory JJ 169 177 activity activity NN 178 180 of of IN 181 193 cyclosporine cyclosporine NN 193 194 . . . 196 198 We we PRP 199 203 have have VBP 204 216 demonstrated demonstrate VBN 217 224 earlier earlier RBR 225 229 that that IN 230 233 the the DT 234 246 crosslinkage crosslinkage NN 247 249 of of IN 250 253 the the DT 254 261 CD3/TCR CD3/TCR NNP 262 269 complex complex NN 270 274 with with IN 275 278 the the DT 279 282 CD2 cd2 NN 283 290 antigen antigen NN 291 298 results result VBZ 299 301 in in IN 302 305 the the DT 306 319 proliferation proliferation NN 320 322 of of IN 323 329 normal normal JJ 330 335 human human JJ 336 337 T t NN 338 343 cells cell NNS 343 344 . . . 345 348 The the DT 349 355 effect effect NN 356 358 of of IN 359 363 this this DT 364 373 synergism synergism NN 374 377 was be VBD 378 389 perceptible perceptible JJ 390 392 at at IN 393 396 the the DT 397 402 level level NN 403 405 of of IN 406 415 induction induction NN 416 418 of of IN 419 422 the the DT 423 427 IL-2 il-2 NN 428 432 gene gene NN 432 433 , , , 434 435 a a DT 436 443 process process NN 444 452 critical critical JJ 453 456 for for IN 457 458 T t NN 459 463 cell cell NN 464 470 growth growth NN 470 471 . . . 472 474 To to TO 475 482 further further RB 483 493 understand understand VB 494 497 the the DT 498 507 molecular molecular JJ 508 511 and and CC 512 519 nuclear nuclear JJ 520 525 basis basis NN 526 529 for for IN 530 534 this this DT 535 544 synergism synergism NN 544 545 , , , 546 548 we we PRP 549 553 have have VBP 554 562 explored explore VBN 563 566 the the DT 567 576 induction induction NN 577 579 of of IN 580 591 DNA-binding dna-binding JJ 592 600 proteins protein NNS 601 603 in in IN 604 610 highly highly RB 611 619 purified purify VBN 620 626 normal normal JJ 627 632 human human JJ 633 634 T t NN 635 640 cells cell NNS 641 649 signaled signal VBN 650 653 via via IN 654 657 the the DT 658 661 CD3 cd3 NN 662 668 and/or and/or CC 669 672 CD2 cd2 NN 673 681 proteins protein NNS 681 682 . . . 683 686 The the DT 687 693 effect effect NN 694 696 of of IN 697 710 transmembrane transmembrane NN 711 720 signaling signaling NN 721 723 of of IN 724 725 T t NN 726 731 cells cell NNS 732 736 with with IN 737 746 ionomycin ionomycin NN 746 747 , , , 748 754 and/or and/or CC 755 761 sn-1,2 sn-1,2 NN 762 772 dioctanoyl dioctanoyl NN 773 781 glycerol glycerol NN 781 782 , , , 783 786 was be VBD 787 791 also also RB 792 802 determined determine VBN 802 803 . . . 804 807 The the DT 808 817 emergence emergence NN 818 820 of of IN 821 828 nuclear nuclear JJ 829 836 binding binding NN 837 845 proteins protein NNS 846 849 was be VBD 850 862 investigated investigate VBN 863 868 using use VBG 869 882 interleukin-2 interleukin-2 NN 883 891 sequence sequence NN 892 900 specific specific JJ 901 916 oligonucleotide oligonucleotide NN 917 923 probes probe NNS 924 926 in in IN 927 930 the the DT 931 946 electrophoretic electrophoretic JJ 947 955 mobility mobility NN 956 961 shift shift NN 962 967 assay assay NN 967 968 . . . 969 972 Our our PRP$ 973 980 studies study NNS 981 992 demonstrate demonstrate VBP 993 996 for for IN 997 1000 the the DT 1001 1006 first first JJ 1007 1011 time time NN 1012 1016 that that IN 1017 1020 CD3 cd3 NN 1021 1036 antigen-derived antigen-derived JJ 1037 1044 signals signal NNS 1045 1048 and and CC 1049 1052 CD2 cd2 NN 1053 1068 antigen-derived antigen-derived JJ 1069 1076 signals signal NNS 1077 1080 are be VBP 1081 1092 synergistic synergistic JJ 1093 1095 in in IN 1096 1104 inducing induce VBG 1105 1108 the the DT 1109 1118 emergence emergence NN 1119 1121 of of IN 1122 1135 transcription transcription NN 1136 1143 factors factor NNS 1144 1148 that that WDT 1149 1153 bind bind VBP 1154 1156 to to TO 1157 1160 the the DT 1161 1167 NF-AT1 nf-at1 NN 1167 1168 , , , 1169 1173 AP-1 ap-1 NN 1173 1174 , , , 1175 1178 and and CC 1179 1184 NF-kB NF-kB NNP 1185 1190 sites site NNS 1191 1198 located located JJ 1199 1201 in in IN 1202 1205 the the DT 1206 1223 promoter/enhancer promoter/enhancer NN 1224 1230 region region NN 1231 1233 of of IN 1234 1237 the the DT 1238 1242 IL-2 il-2 NN 1243 1247 gene gene NN 1247 1248 . . . 1249 1257 Moreover moreover RB 1257 1258 , , , 1259 1271 cyclosporine cyclosporine NN 1271 1272 , , , 1273 1275 at at IN 1276 1290 concentrations concentration NNS 1291 1298 readily readily RB 1299 1311 accomplished accomplish VBN 1312 1314 in in IN 1315 1323 clinical clinical JJ 1324 1332 practice practice NN 1332 1333 , , , 1334 1337 was be VBD 1338 1343 found find VBN 1344 1346 to to TO 1347 1354 inhibit inhibit VB 1355 1358 the the DT 1359 1368 emergence emergence NN 1369 1371 of of IN 1372 1377 these these DT 1378 1389 DNA-binding dna-binding JJ 1390 1398 proteins protein NNS 1399 1401 in in IN 1402 1408 normal normal JJ 1409 1414 human human JJ 1415 1416 T t NN 1417 1422 cells cell NNS 1423 1431 signaled signal VBN 1432 1435 via via IN 1436 1440 cell cell NN 1441 1448 surface surface NN 1449 1457 proteins protein NNS 1458 1468 implicated implicate VBN 1469 1471 in in IN 1472 1489 antigen-dependent antigen-dependent JJ 1490 1491 T t NN 1492 1496 cell cell NN 1497 1507 activation activation NN 1508 1511 and and CC 1512 1514 in in IN 1515 1516 T t NN 1517 1522 cells cell NNS 1523 1533 stimulated stimulate VBN 1534 1536 by by IN 1537 1549 mobilization mobilization NN 1550 1552 of of IN 1553 1561 cellular cellular JJ 1562 1569 calcium calcium NN 1570 1573 and and CC 1574 1584 activation activation NN 1585 1587 of of IN 1588 1595 protein protein NN 1596 1602 kinase kinase NNP 1603 1604 C C NNP 1604 1605 . . .